Drug Trial Radar · NCT06934252
Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
115
Planned (sponsor's estimate)
Start
May 2, 2025
Primary completion
Sep 2, 2027
Study completion Feb 29, 2028
Sponsor
- Lead sponsor
- TRex Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1a/1b randomized, double-blind, placebo-controlled study evaluates the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously (SC) administered TRB-061 in healthy adults and patients with moderate-to-severe atopic dermatitis (AD). The number of dosing cohorts may be increased or decreased in Part 1 (SAD) or Part 2 (MAD). Part 1 (SAD): Healthy participants receiving single doses of TRB-061 or placebo. Part 2 (MAD): Healthy participants receiving multiple doses (3 doses over 8 weeks) of TRB-061 or placebo. Part 3 (Phase 1b): Participants with moderate-to-severe AD receiving repeated doses (4 doses over 12 weeks) of TRB-061 or placebo.
Conditions
- Moderate-to-severe Atopic Dermatitis
Interventions
TRB-061Drug
Single subcutaneous injection of TRB-061 at escalating doses
TRB-061Drug
Subcutaneous TRB-061 administered every 4 weeks for a total of 4 doses
TRB-061Drug
Subcutaneous TRB-061 administered every 4 weeks for 3 doses
PlaceboDrug
Single and multiple subcutaneous doses of placebo matching TRB-061 in patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Screening to Day 85 (SAD), Up to Day 127 (MAD); up to Day 253 (Phase 1b)
Locations
19 sites in 2 countries. Site status is shown where the registry gives one.
Alfred Health
Melbourne, Australia · Recruiting
MCR Sunshine
Saint Albans, Australia · Recruiting
Paratus Clinical Research - Canberra Trial Clinic
Deakin, Australian Capital Territory, Australia · Recruiting
Paratus Clinical Brisbane Pty Ltd
Albion, Brisbane, Australia · Recruiting
Paratus Clinical Research Western Sydney
Blacktown, New South Wales, Australia · Recruiting
Paratus Clinical Research Central Coast
Kanwal, New South Wales, Australia · Recruiting
Cornerstone Centre for Clinical Research
Coorparoo, Queensland, Australia · Recruiting
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, Australia · Active not recruiting
Paratus Clinical Research Melbourne
Melbourne, Victoria, Australia · Recruiting
Pacific Clinical Research Network-West Auckland
Auckland, New Zealand · Recruiting
MCR Christchurch
Christchurch, New Zealand · Recruiting
MCR Palmerston North
Palmerston North, New Zealand · Recruiting
Momentum Clinical Research Pukekohe
Pukekohe, Auckland, New Zealand · Recruiting
Momentum Clinical Research Dunedin
Dunedin, Otago, New Zealand · Recruiting
Pacific Clinical Research Network-Tasman
Nelson, Tasman District, New Zealand · Recruiting
Clinical Trials New Zealand Ltd
Hamilton, Waikato Region, New Zealand · Recruiting
Medical Research Institute of New Zealand
Newtown, Wellington Region, New Zealand · Recruiting
Pacific Clinical Research Network-Wellington
Upper Hutt, Wellington Region, New Zealand · Recruiting
Momentum Clinical Research Kapiti
Waikanae, Wellington Region, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.